Below you'll find a list of all posts that have been tagged as “China”
Top leadership in Beijing has faced difficult decisions over the previous weeks. Though new cases of COVID-19 continue to see a downward trend, much of this can be attributed to the fast and firm response of the officials, with the shutting down of crowded public spaces and city centres being just some examples of the measures taken. Senior figures in …
China has always been an attractive destination for researchers in the healthcare sector because of its size and population, and the scale of studies thus made possible. Until recently, though, its regulatory system was cumbersome and not well designed for foreigners, who found it hard to understand what was required of them. Thankfully, the past couple of years have seen …
Twenty years ago, China’s biotech industry was worth around $2.4bn. This year, its revenues are expected to exceed $1.2tn. That’s a remarkable achievement by any standards, and one that has understandably led to excitement among investors and industry professionals alike. How has it been achieved? How has the sector actually changed and what can we expect to see in the …
A report released in February by US-based Research and Markets addresses the shift in China away from low volume, high value manufacturing as a major catalyst for the increasing growth rate of China’s pharmaceutical market. The country now holds, at minimum, an 8 – 10% market share globally. The report goes on to state that greater technological advancements could quickly …
The Chinese pharmaceutical market sees another significant victory in recent weeks as it is announced that China has conditionally approved the first new Alzheimer’s drug to hit the global market in 17 years, and it will be distributed worldwide for long-term testing. The seaweed-derived drug GV-971, more colloquially known as Oligomannate, appears to improve cognition in patients with mild to …
